# Keisuke Kirita

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/keisuke-kirita/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,349 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 21 |
| i10-index | 34 |
| Last Known Institution | Hakodate Central General Hospital |
| OpenAlex ID | https://openalex.org/A5057508798 |
| ORCID iD | 0000-0003-4998-1826 |
| Works | 93 |

## Researcher papers

- [The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies](https://scholariq.org/papers/the-pd-1-expression-balance-between-effector-and-regulatory-t-cells-predicts-the/)
- [Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study](https://scholariq.org/papers/randomized-phase-2-study-of-osimertinib-plus-bevacizumab-versus-osimertinib-for/)
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without/)
- [Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden](https://scholariq.org/papers/non-small-cell-lung-cancer-with-loss-of-expression-of-the-swi-snf-complex-is/)
- [Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report](https://scholariq.org/papers/successful-treatment-with-nivolumab-for-smarca4-deficient-non-small-cell-lung/)
- [The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer](https://scholariq.org/papers/the-clip1-ltk-fusion-is-an-oncogenic-driver-in-non-small-cell-lung-cancer/)
- [Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: Prospective single‐arm study](https://scholariq.org/papers/feasibility-and-utility-of-transbronchial-cryobiopsy-in-precision-medicine-for/)
- [Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer](https://scholariq.org/papers/association-of-serum-anti-gad-antibody-and-hla-haplotypes-with-type-1-diabetes/)
- [A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)](https://scholariq.org/papers/a-phase-ii-study-of-osimertinib-for-radiotherapy-naive-central-nervous-system/)
- [CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors](https://scholariq.org/papers/cd200-positive-cancer-associated-fibroblasts-augment-the-sensitivity-of/)
- [Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer](https://scholariq.org/papers/bronchoscopic-re-biopsy-for-mutational-analysis-of-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)

## Researcher university

- [Hakodate Central General Hospital](https://scholariq.org/institutions/hakodate-central-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.